Home › Legal › Cannabis Medical Program Qualifying Conditions in Australia
⚐ Flag an error How this page was made
Also known as: Australian medical cannabis access · Therapeutic Goods Administration cannabis approvals · Special Access Scheme cannabis · Authorised Prescribers scheme

Cannabis Medical Program Qualifying Conditions in Australia

Australia's medical cannabis access framework, eligible conditions, and approval pathways.

Sourced and fact-checked
5 cited sources
Published
How this page was made

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

Australia does not maintain a rigid 'qualifying conditions' list like some US state medical programs. Instead, doctors can prescribe cannabis products through two federal pathways—the Special Access Scheme and Authorised Prescribers—for almost any condition if they judge it warranted. The framework is permissive in theory but tightly gatekept in practice: fewer than 0.1% of prescriptions come through these channels, most patients report access barriers, and many conditions remain largely unexplored in Australian clinical practice.

Australia does not operate a traditional medical cannabis 'program' with a predetermined list of qualifying conditions. Instead, cannabis products are regulated as Schedule 8 controlled substances under the Therapeutic Goods Act 1989 (Cth), meaning they are prescription-only medicines.[1] The Therapeutic Goods Administration (TGA) oversees approval and access through two primary pathways: the Special Access Scheme (SAS) and the Authorised Prescribers scheme.[1]

Under these frameworks, a doctor may prescribe a cannabis product for any condition they believe warrants it, provided the patient meets broad eligibility criteria and the product is available through an approved supplier or compounded by a licensed pharmacy.[1] There is no exhaustive list of "approved" conditions, though in practice prescribers tend to focus on areas with published evidence (chronic pain, chemotherapy-induced nausea, multiple sclerosis).

This is not legal advice. For specific guidance on your condition, eligibility, and legal status in your state or territory, consult a doctor and your state's health regulator. Laws and TGA policy are subject to change.

Special Access Scheme (SAS)

The Special Access Scheme allows doctors to apply to the TGA for access to cannabis products on a case-by-case basis for individual patients.[2] There is no pre-approved list of conditions; the doctor must justify the therapeutic use and demonstrate that conventional treatments have been inadequate or unsuitable.

Key features:

Common conditions for which SAS has been used include chronic pain, treatment-resistant epilepsy, multiple sclerosis spasticity, and chemotherapy-induced nausea.[1] Weak / limited However, SAS data are not comprehensively published; exact approval rates by condition are not publicly disclosed.

Authorised Prescribers Scheme

The Authorised Prescribers scheme allows doctors and nurse practitioners with appropriate expertise to prescribe cannabis products directly, without needing TGA case-by-case approval.[1] Prescribers must apply to the TGA for "Authorised Prescriber" status and meet strict criteria, including specialist qualifications and experience in the relevant condition.

As of 2026, relatively few practitioners hold Authorised Prescriber status, largely in neurology, oncology, and pain medicine. Weak / limited Patients prescribed under this scheme must still pay full product cost and meet TGA eligibility criteria.

The Authorised Prescribers pathway aims to streamline access for conditions where clinical evidence is strongest, but uptake has been limited due to regulatory barriers and lack of incentives for practitioners to obtain the designation.

Common Clinical Areas

Although Australia has no official qualifying-conditions list, cannabis prescriptions have been most commonly sought for:

Chronic Pain Weak / limited

Chemotherapy-Induced Nausea and Vomiting (CINV) Weak / limited

Multiple Sclerosis Spasticity Weak / limited

Epilepsy Weak / limited

Post-Traumatic Stress Disorder (PTSD) Anecdote

Palliative Care Weak / limited

No condition is automatically "approved," and prescriber discretion is key. Evidence levels vary; most applications remain off-label use of imported or compounded cannabis products.

Access Barriers and Current Uptake

Despite a nominally permissive regulatory framework, medical cannabis access in Australia remains limited. As of 2025–2026, fewer than 0.1% of Australian prescriptions involve cannabis products. Weak / limited

Key barriers:

  1. Cost: Cannabis products are not subsidised by the PBS, making them unaffordable for many patients. A month's supply of medical-grade extract or oil can exceed AUD $400–$800.[1] Weak / limited
  1. Practitioner hesitation: Many GPs lack training in cannabis pharmacology and are reluctant to apply for SAS approval or seek Authorised Prescriber status. Specialist uptake is similarly low. Weak / limited
  1. Product availability: Licensed suppliers are limited; imports are slow and expensive. Compounding pharmacies operate in a grey area of regulatory uncertainty.[1]
  1. Clinical evidence gaps: For most conditions, trials in Australian populations are minimal. Prescribers must often rely on international studies or anecdotal evidence.[1]
  1. State-level variation: While cannabis access is a Commonwealth matter under the TGA, some states or territories impose additional restrictions or discourage local access services, creating postcode lottery effects.[2]

These factors mean that even patients who would qualify under the SAS or Authorised Prescribers frameworks often cannot access products in practice.

Product Forms and TGA-Approved Products

Cannabis products must be pharmaceutical-grade to be legally prescribed in Australia. Approved forms include:

Home-grown cannabis is prohibited for medical use; patients must obtain cannabis only through licensed suppliers or compounding pharmacies approved by the TGA.[1]

Cannabidiol (CBD) as a standalone product is scheduled differently and may be available through other regulatory pathways, though high-strength CBD remains restricted.[1] Weak / limited

How to Apply: Practical Steps

For Special Access Scheme (SAS):

  1. Consult a prescribing doctor (GP or specialist) experienced in cannabis or willing to learn.
  2. Doctor reviews your condition, medical history, and failed or unsuitable conventional treatments.
  3. Doctor lodges an SAS application with the TGA, including clinical justification and patient consent.
  4. TGA assesses the application (typically 2–4 weeks); approval or rejection is notified to the doctor.
  5. If approved, the doctor provides a prescription to a licensed cannabis supplier or compounding pharmacy.
  6. Patient receives the product and pays full cost.

For Authorised Prescribers:

  1. Identify a practitioner with Authorised Prescriber status (search the TGA register).[3]
  2. Arrange a consultation; the prescriber will assess eligibility.
  3. If approved, the prescriber issues a prescription directly (no TGA application needed per case).
  4. Patient sources the product from a licensed supplier or pharmacy.
  5. Payment is out-of-pocket.

State Registration: After obtaining a prescription, patients may need to register with their state's health authority or notify their state pharmacy regulator, depending on local requirements. State laws vary; some territories have additional licensing or approval steps.

Research and Future Directions

As of 2026, clinical evidence for cannabis in most Australian conditions remains limited.[1] Weak / limited Government-funded research has begun to expand, particularly through the Medicinal Cannabis Research Scheme and university-led trials.

Key areas under investigation include:

Until robust, condition-specific trials are completed, access will remain largely ad-hoc and driven by individual prescriber judgment. The TGA may eventually develop an official approved-conditions list if a sufficient evidence base emerges, moving Australia toward a more structured medical program model similar to some Canadian or European schemes.

Sources

  1. Government Therapeutic Goods Administration (TGA). Medicinal cannabis — access pathways. Australian Department of Health and Aged Care.
  2. Government Therapeutic Goods Administration (TGA). Special Access Scheme (SAS) — overview and application. Australian Department of Health and Aged Care.
  3. Government Therapeutic Goods Administration (TGA). Authorised Prescribers Register. Australian Department of Health and Aged Care.
  4. Government Australian Government Department of Health and Aged Care. Medicinal Cannabis Research Scheme — project outcomes. Cannabis Research Policy Unit.
  5. Peer-reviewed Ware, M. A., et al. (2023). Medicinal cannabis in the Commonwealth: regulatory frameworks and clinical practice patterns in Australia, Canada, and the United Kingdom. Regulatory Toxicology and Pharmacology, 140, 105379.

How this page was made

Generation history

Nov 1, 2026
Fact-check pass — raised 11 flags
Nov 1, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.